Search the Newsreel

UBS Initiates Alphatec Holdings at Buy With $15 Price Target

UBS has initiated coverage on Alphatec Holdings (NASDAQ: ATEC) with a "Buy" rating and a price target of $15. This follows similar initiations from Stephens and BMO Capital with "Overweight" and "Outperform" ratings, respectively. The medical device company, focused on spinal disorder treatment, has …

Alphatec Holdings Inc (ATEC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Alphatec Holdings Inc (ATEC), detailing its price momentum, support and resistance levels, and the readings from various technical indicators and moving averages. As of the analysis, ATEC's price momentum score is 4.02 and the stock is trading …

Paradeep Phosphates approves ₹250 crore Aluminium Fluoride plant

Paradeep Phosphates Q1 Net Profit Stands at ₹3.93 Billion

Paradeep Phosphates approves 20 lakh stock options in new 2026 plan

Alphatec Holdings Inc (ATEC) Risk Assessment: Volatility, Financial Risk & Investment Risk

Alphatec Holdings Inc (ATEC) has a current risk assessment score of 6.27, placing it 59th out of 199 in the Healthcare Equipment & Supplies industry. The stock's beta of 0.90 suggests it is less volatile than the S&P 500. The article details various risk …

ATEC|Alphatec Holdings Inc|Price:8.670|Chg%:+0.410

This article provides a comprehensive stock analysis of Alphatec Holdings Inc (ATEC) by TradingKey. It highlights the company's relatively stable fundamentals, high growth potential (averaging 58.45% revenue growth over 3 years), and fair valuation within the Healthcare Equipment & Supplies industry. Despite recent weak …

ATEC Announces Participation in Upcoming Investor Conferences

CARLSBAD, Calif., July 27, 2026--(BUSINESS WIRE)--Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will participate in the following investor conference(s): Management will host one-on-one investor meetings at the 11th Annual …

Phathom Pharmaceuticals Inc (PHAT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Phathom Pharmaceuticals Inc (PHAT) but states that relevant data for business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly presents current stock information, including the stock price, market cap, …

SummitTX Capital L.P. Purchases 478,065 Shares of Phathom Pharmaceuticals, Inc. $PHAT

SummitTX Capital L.P. increased its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) by 92.3% in the first quarter, acquiring an additional 478,065 shares, bringing its total holdings to 995,885 shares valued at approximately $11.1 million. Other institutional investors also adjusted their positions in PHAT, which …

Rama Phosphates Share Price Gains on Q1 Results

Paradeep Phosphates Q1 Results: Earnings call scheduled for July 31

Phathom Pharmaceuticals Inc (PHAT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Phathom Pharmaceuticals Inc (PHAT)'s dividend and stock split history, noting that no dividends have been distributed over the past five years. It also includes current stock performance data and market capitalization for PHAT.

Alphatec Holdings, Inc. Revenue Breakdown – DUS:L1Z1

This article provides a revenue breakdown for Alphatec Holdings, Inc. (DUS:L1Z1). Last year, the company generated 650.62 million EUR, with its top-performing segment, Spinal Surgery Implants, contributing the entire amount. The United States was the greatest regional contributor, accounting for 609.74 million EUR of …

Enterprise value to revenue forward of Alphatec Holdings, Inc. – MUN:L1Z1

This article focuses on the enterprise value to revenue forward metric for Alphatec Holdings, Inc. (MUN:L1Z1). It appears to be a financial data point presented on a trading platform, indicating the company's valuation in relation to its future revenue. The content mainly consists of …

Rama Phosphates Q1FY27 net profit rises 6.4% to ₹1,706.44 lakhs on revenue surge

Rama Phosphates Q1 FY27 results: profit up 6.4%

Rama Phosphates standalone net profit rises 6.43% in the June 2026 quarter

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Phathom Pharmaceuticals (NASDAQ:PHAT) has received a "Moderate Buy" consensus rating from seven analysts, with an average 12-month price target of $24.50. Recent analyst actions show mixed views, including an upgrade to "overweight" by Barclays and a reiterated "sell" from Weiss Ratings, while HC Wainwright …

Alphatec (ATEC) Wells Fargo 20th Annual Healthcare Conference 2025 Summary

Alphatec (ATEC) presented a summary of its financial performance, market strategy, and product development at the Wells Fargo 20th Annual Healthcare Conference 2025. The company highlighted sustained revenue growth, expanded profitability, and projections for positive free cash flow. Key initiatives include surgeon engagement, sales …

ATEC|Alphatec Holdings Inc|Price:8.200|Chg%:+0.140

Alphatec Holdings Inc (ATEC) shows stable fundamentals and high growth potential, though its stock price is expected to trend down in the medium term despite strong fundamentals. The company is considered fairly valued in the Healthcare Equipment & Supplies industry. Analysts currently rate ATEC …

Alphatec (ATEC) Barclays 28th Annual Global Healthcare Conference Summary

Alphatec (ATEC) presented a summary of its performance and strategy at the Barclays 28th Annual Global Healthcare Conference. The company emphasized strong growth, profitability, and market share gains driven by clinical distinction and procedural solutions. Key growth drivers include surgeon adoption, increasing utilization, and …

Stephens Initiates Alphatec Holdings at Overweight With $15 Price Target

Stephens has initiated coverage on Alphatec Holdings (ATEC) with an "Overweight" rating and a $15 price target. This follows BMO Capital's earlier "Outperform" initiation with an $11 price target in July. The medical device company focuses on technology for surgical treatment of spine disorders.

Stephens initiates Alphatec stock with Overweight on spine surgery strategy By Investing.com

Stephens initiated coverage on Alphatec Holdings (NASDAQ:ATEC) with an Overweight rating and a $15.00 price target, viewing the company as a disruptor in spine surgery through its proceduralization strategy. Despite recent stock underperformance due to concerns about surgical growth durability and EOS execution, Stephens …

Phathom Pharmaceuticals (PHAT) to Post Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is slated to release its Q2 2026 financial results on Thursday, July 30th, with analysts forecasting a loss of $0.06 per share on revenues of $73.4 million. The company's stock is currently trading around $11.70, below its 52-week high, and has …

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Report - Results, Call & Slides

Phathom Pharmaceuticals, Inc. (PHAT) released its Q1 2025 earnings report, missing both EPS and revenue expectations. The company reported an actual EPS of -$1.31 against a consensus of -$1.10 and actual revenue of $28.52M versus an expected $29.02M, though revenue saw a significant year-over-year …

Alphatec Holdings, Inc. (ATEC): Investor Outlook Highlights Nearly 93% Upside Potential

Alphatec Holdings, Inc. (ATEC), a medical device company focused on spinal disorders, shows significant growth potential with an average analyst target price suggesting a 93.47% upside. Despite current unprofitability with a negative EPS of -0.80, the company boasts strong revenue growth of 13.60% and …

Guggenheim Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $25

Guggenheim has reiterated its Buy rating on Phathom Pharmaceuticals (PHAT.US), maintaining a target price of $25. This indicates continued confidence from the analyst firm in the company's stock performance.

Millennium group discloses 4.2% Phathom (PHAT) stake in amended ownership filing

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have disclosed a 4.2% beneficial ownership stake in Phathom Pharmaceuticals, Inc. through an amended Schedule 13G/A filing. This equates to 3,375,834 shares, all of which are held with shared voting and shared dispositive …

Avoiding Lag: Real-Time Signals in (PHAT) Movement

This article analyzes Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) using AI models, highlighting conflicting sentiment across different time horizons, suggesting choppy market conditions. It outlines distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels, and details multi-timeframe signal analysis …

Phathom Pharma schedules second-quarter earnings webcast

Phathom Pharmaceuticals will report its second-quarter 2026 results on July 30, 2026, accompanied by a business update during an 8:00 a.m. EDT webcast. The event details and webcast link are available on the investor relations section of Phathom Pharma's website. This news brief was …

Phathom plans July 30 update on its gastrointestinal treatments

Phathom Pharmaceuticals will host a live webcast on Thursday, July 30, 2026, at 8:00 am EDT to report its second quarter 2026 financial results and provide a business update. The company focuses on developing and commercializing novel treatments for gastrointestinal diseases, including vonoprazan-based products …

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

Phathom Pharmaceuticals announced it will host a live webcast on Thursday, July 30, 2026, at 8:00 am EDT to report its second quarter 2026 financial results and provide a business update. The biopharmaceutical company, focused on GI diseases, will make the webcast accessible on …

ATEC6342884 Bond Risk Profile

This article provides a risk profile for the ATEC6342884 bond, specifically Alphatec Holdings, Inc. 0.75% 15-MAR-2030, accessible through TradingView. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate reliability. The platform also offers …

ATEC6342884 Bond Coupon Profile — Rate & Payments

This article provides a bond coupon profile for Alphatec Holdings, Inc. bond ATEC6342884, detailing its interest rate and payment schedule. The bond has a current coupon rate of 0.75%, with the next payment scheduled for September 15, 2026. The profile offers an in-depth breakdown …

ATEC6342884 Bond Profile — Key Metrics

This article provides key metrics for the ATEC6342884 bond profile, issued by Alphatec Holdings, Inc. The bond is a 0.75% bond maturing on March 15, 2030, with an outstanding amount of 405 million USD. Alphatec Holdings specializes in spinal fusion technology products and solutions.